Most regulatory leaders we speak with are not struggling because their teams lack expertise. They’re struggling because the operational infrastructure around their teams hasn’t kept up with what’s being asked of them.
In the last three years, the volume of global regulatory submissions has increased significantly while headcount has stayed flat. Regulatory authorities in the EU, US, UK, and across APAC have each introduced substantial updates: EU MDR and IVDR transition deadlines, FDA’s QMSR rule replacing 21 CFR Part 820, and an expanding wave of country-specific digital health requirements. Regulatory teams are absorbing all of this while still being expected to accelerate time to market.
What we see across the companies using RegDesk’s platform are insightful. The delays, compliance gaps, and submission errors teams experience in 2026 are almost never the result of a knowledge problem. They’re the result of a process and visibility problem; one that compounds quickly when you’re managing 10, 20, or 50+ markets simultaneously.
This post breaks down the seven core struggles regulatory teams are facing right now, with practical context on where the friction actually lives and how leading teams are addressing it.
Why Regulatory Teams Are Under More Pressure Than Ever
Four converging forces explain why regulatory operations are harder today than they were even three years ago:
Global regulatory complexity has compounded. There is no single global framework for medical device regulation. Each major market (FDA 510(k)/PMA, EU MDR, Health Canada, TGA, ANVISA, NMPA) has distinct requirements, timelines, and documentation expectations. As companies expand into emerging markets in Southeast Asia, Latin America, and the Middle East, the matrix of requirements grows faster than teams can manage manually.
The pace of regulatory change has accelerated. From FDA’s final QMSR rule to the EU MDR Article 120 transition deadlines, 2024 and 2025 saw a burst of regulatory updates that teams are still absorbing. Guidance documents are issued, withdrawn, and revised with a frequency that is difficult to track without a dedicated intelligence system.
Submission volumes keep growing. Portfolio expansion, post-market obligations, and increasingly granular change notification requirements mean more submissions, even for companies with stable product lines.
Speed expectations have not softened. Business leadership expects regulatory timelines to compress, not expand. The pressure to move faster exists regardless of what’s happening on the regulatory landscape.
Overview: Seven Key Challenges Facing Regulatory Teams in 2026
The table below summarizes what we’re hearing and seeing most consistently across regulatory teams in MedTech:
| Regulatory Challenge | Root Cause | Business Impact |
|---|---|---|
| Global Regulatory Complexity | 100+ regulatory frameworks worldwide | Submission delays, market access gaps |
| Constant Regulatory Changes | No real-time intelligence system | Compliance gaps, rework costs |
| Manual Processes & Inefficiencies | Spreadsheets, disconnected tools | Up to 40% of team time on admin tasks |
| Fragmented Regulatory Data | Data silos across regions/teams | Inconsistency, version control failures |
| Cross-Functional Misalignment | No shared visibility across workflows | Delayed handoffs, duplicated work |
| Scaling Global Operations | Headcount can’t keep up with volume | Bottlenecks, missed market windows |
| Submission Delays & Rejections | Poor tracking, documentation errors | Rejection rates, increased audit risk |
Challenge 1: Managing Global Regulatory Complexity
Ask any regulatory director managing more than five markets what takes up the most bandwidth, and the answer is almost always the same: keeping track of what each country actually requires right now and whether those requirements have changed since the last submission.
The number of active regulatory frameworks a typical mid-size MedTech company must navigate has grown considerably. FDA, EU MDR/IVDR, Health Canada, TGA (Australia), PMDA (Japan), NMPA (China), Anvisa (Brazil), and CDSCO (India) each operate on distinct submission formats, clinical evidence standards, and post-market surveillance expectations. Country-specific requirements below that level such as labeling language, authorized representative obligations, in-country testing requirements all add another layer of complexity.
What makes this genuinely hard to manage is not any single framework. It’s the combination of managing all of them simultaneously, where a product change in one market can trigger notification requirements in a dozen others, each with different thresholds and timelines.
Challenge 2: Keeping Up with Constant Regulatory Changes
Regulatory intelligence refers to knowing what has changed, what is about to change, and what it means for your submissions and registrations. This has become one of the most time-intensive activities for regulatory teams. And most teams are still doing it manually.
The typical approach involves monitoring agency websites, subscribing to regulatory alerts, and relying on individual team members to surface relevant updates. This works up to a point. But with the volume of guidance documents, consultation papers, and regulatory notices being issued across 20+ markets, manual monitoring creates systematic gaps.
Updates get missed. Their implications don’t get assessed in time. Submissions go out based on requirements that were superseded three months earlier.
The risk is not hypothetical. FDA’s QMSR rule (which replaced 21 CFR Part 820 with ISO 13485-aligned requirements effective February 2026) caught a meaningful number of companies underprepared despite years of advance notice, simply because the operational implications were not fully absorbed until the deadline was close.
- Teams should maintain a structured regulatory watch list organized by market and product category
- Changes should be triaged by impact: which submissions, registrations, or compliance activities does this affect?
- That triage needs to happen quickly; not in a quarterly review cycle
Challenge 3: Manual Processes and Operational Inefficiencies
Regulatory operations in 2026 still run on spreadsheets at most companies. This is not a criticism because spreadsheets are flexible, accessible, and familiar. However, they are not built for the operational demands of global regulatory management, and the gap between what teams need and what spreadsheets can deliver is widening.
The specific inefficiencies we see most consistently include:
- Duplicate documentation work: The same product data entered separately into multiple country submission packages
- Version control failures: Teams working from outdated templates or regulatory data without realizing it
- Submission tracking via email threads and manually updated status logs
- Rework cycles caused by inconsistencies between what regulatory submitted and what quality or clinical has on file
Collectively, these inefficiencies consume a significant share of regulatory team capacity. Time that would otherwise go toward strategic work, submission quality review, or proactive compliance planning. The teams that have moved to structured, centralized regulatory operations consistently report meaningful reductions in preparation time per submission.
Challenge 4: Fragmented Regulatory Data and Documentation
Regulatory data such as product specifications, clinical evidence summaries, registration certificates, correspondence histories, and technical file components is typically scattered across shared drives, email folders, local hard drives, and legacy systems. In larger organizations, it’s fragmented across regional teams as well.
The downstream effects of this fragmentation are significant. When a regulatory team needs to prepare a variation submission for an existing product, the first step is often an internal search project. First, by locating the original submission, then confirming the current approved labeling, and finally, finding the most recent audit correspondence, and reconciling which version of the technical file is current. That search can take hours or days.
Version control is a related and equally serious problem. Multiple versions of the same document circulating across a team creates submission risk. Errors that originate from documentation inconsistency are among the most common triggers for Requests for Additional Information (RAIs) from regulatory authorities.
Challenge 5: Cross-Functional Coordination Challenges
Regulatory submissions do not get prepared in isolation. They depend on inputs from clinical teams, quality, R&D, manufacturing, and legal. When those functions operate in separate systems with separate workflows, coordination becomes a significant source of delay.
The specific friction points vary by organization, but the pattern is consistent with regulatory teams often waiting on inputs from other functions, chasing approvals through email, and reconciling conflicting information between what different teams have on file.
Handoffs that should take hours take days. Reviews that are meant to be parallel happen sequentially. Deadlines slip not because anyone made a mistake, but because the workflow was never structured to support the pace the business requires.
Post-market obligations compound this problem. MDR Article 10 reporting requirements, FDA MDR obligations, and PMCF/SSCP documentation under EU MDR all require close coordination between regulatory, clinical, and quality sustained over the product lifecycle, not just at initial submission.
Challenge 6: Scaling Regulatory Operations Globally
Growth creates a specific regulatory operations problem that is underappreciated. As companies add products and markets, the volume of regulatory work grows faster than headcount.
A company entering its fifth global market can usually absorb the additional workload. A company entering its fifteenth, while simultaneously managing post-market obligations across its existing portfolio and preparing next-generation submissions, typically cannot; not without a structural change in how regulatory operations are organized.
The companies that scale most effectively do two things differently. First, they treat regulatory data and process standardization as an investment, not overhead so that adding a new market or product doesn’t require building an entirely new workflow from scratch. Second, they adopt systems that allow them to reuse regulatory assets: existing technical documentation, previously validated clinical claims, established labeling frameworks. Reuse at scale is only possible when regulatory data is organized and accessible.
Challenge 7: Submission Delays and Compliance Risks
Submission delays are the visible symptom of the underlying process problems described above. But they carry real costs due to delayed approvals which translate directly into delayed revenue, missed market windows, and competitive disadvantage.
The most common causes of submission delays we observe are not clinical or technical; they’re operational. Missing or inconsistent documentation. Status tracking that doesn’t surface approaching deadlines until they’re imminent.
Internal review cycles that weren’t planned far enough in advance. These are solvable problems, but they require deliberate process design rather than heroic individual effort.
Compliance risk is a related but distinct concern. As regulatory authorities increase inspection frequency and scrutiny, the EU notified body audit backlog has created intensified pressure on companies to demonstrate robust quality management systems causing the cost of compliance gaps to rise. Findings that result in Warning Letters, import alerts, or registration suspensions are significantly more expensive to remediate than the investments required to prevent them.
How Leading Regulatory Teams Are Addressing These Challenges
The regulatory teams that are managing these pressures most effectively in 2026 share several operational characteristics:
They have standardized their processes across regions. Rather than allowing each market or product line to develop its own submission workflow, they maintain a consistent framework that can be applied globally and adapted for local requirements. This reduces the learning curve for new markets and makes it easier to spot and correct process gaps.
They have centralized regulatory data. Product information, registration status, submission history, and regulatory correspondence live in one place instead of across a dozen shared drives. This is the single most impactful operational change we see in teams that have made it.
They use regulatory intelligence proactively. Rather than reacting to regulatory changes after they’ve been published and implemented, they monitor regulatory developments systematically and assess implications before they become submission-critical.
They have improved cross-functional visibility. Regulatory workflows are visible to the functions that depend on and contribute to them, reducing the coordination overhead that slows so many submission timelines.
The Role of Technology in Modern Regulatory Teams
Technology is an essential enabler of the operational model that global regulatory teams need in 2026.
The specific capabilities that matter most are:
- Regulatory intelligence platforms that provide structured, curated updates on regulatory changes across global markets. This means not just raw alerts, but contextualized information on what changes mean for specific submission types and product categories.
- Regulatory Information Management Systems (RIMS) that centralize product data, submission records, and registration information in a single, structured platform accessible to the full team.
- Workflow automation that reduces the manual administrative burden on regulatory professionals such as tracking deadlines, routing documents for review, generating submission-ready reports from existing data.
- AI-assisted analysis that helps teams move faster on tasks like gap analysis, document review, and regulatory pathway assessment.
RegDesk is built specifically for this operational model. Teams using RegDesk’s platform report measurable improvements in submission preparation time, submission accuracy, and visibility into regulatory timelines across global markets. The platform addresses the core operational friction points: fragmented data, manual tracking, and lack of real-time intelligence that sit behind most of the challenges described in this post.
The Future of Regulatory Affairs: Where Teams Are Headed
The direction of travel is clear. Regulatory teams are moving from reactive, submission-by-submission operations toward proactive, intelligence-driven regulatory management. The teams that will be positioned most competitively in the next three to five years are those that invest now in the infrastructure of data, process, and technology that makes that shift possible.
AI will play an increasing role, particularly in regulatory intelligence, submission review, and gap analysis. But the value of AI in regulatory operations depends entirely on data quality and process maturity.
Organizations that have centralized and structured their regulatory data will be able to extract significantly more value from AI capabilities than those still operating from spreadsheets and shared drives. Regulatory roles will also evolve.
As automation absorbs more of the administrative and routine analytical work, regulatory professionals will increasingly focus on strategic decisions: regulatory pathway selection, global market prioritization, proactive agency engagement, and risk management. This is a better use of the expertise that regulatory professionals bring but it requires the operational foundation to be in place first.
Final Takeaways
- Regulatory teams in 2026 face a genuine operational challenge (the volume and complexity of global regulatory work has outpaced the infrastructure most teams have in place to manage it)
- The most common sources of delay and compliance risk are not knowledge gaps but process gaps: fragmented data, manual tracking, disconnected workflows, and reactive rather than proactive regulatory intelligence
- Scaling global regulatory operations effectively requires deliberate investment in standardization, data centralization, and systems that allow teams to reuse regulatory assets across submissions and markets
- Technology is not optional at this level of complexity; regulatory intelligence platforms and RIMS systems are essential infrastructure for teams managing multiple markets
- The teams that are managing these challenges most effectively are those that have made the shift from submission-by-submission operations to structured, data-driven regulatory management
Q&A:
What are the biggest challenges for regulatory teams in 2026?
The most significant challenges are managing global regulatory complexity across multiple frameworks simultaneously, keeping pace with continuous regulatory changes without a real-time intelligence system, and the operational inefficiencies created by manual processes and fragmented data. Collectively, these create the conditions for submission delays, compliance gaps, and resource constraints that affect most regulatory teams operating at global scale.
Why are regulatory teams struggling with global compliance?
Global compliance is difficult because there is no unified framework; each major market has distinct requirements, timelines, and documentation standards that must be managed simultaneously. The operational infrastructure most companies have (shared drives, spreadsheets, email-based tracking) was not designed for this level of complexity. As companies expand into additional markets and manage growing post-market obligations, the gap between what teams need and what their tools can provide becomes increasingly consequential.
How can regulatory teams improve efficiency?
The highest-impact efficiency improvements we see come from centralizing regulatory data (so teams stop spending time searching for information and reconciling versions), standardizing submission workflows across regions (so each new submission builds on established processes rather than starting from scratch), and shifting regulatory intelligence from reactive to proactive. Automation can then amplify these gains, but it requires the underlying data and process foundation to be in place first.
What tools help regulatory teams manage submissions and compliance?
Regulatory Information Management Systems (RIMS) provide the central platform for organizing submission data, tracking registration status, and managing regulatory documentation across markets. Regulatory intelligence platforms complement RIMS by providing curated, actionable updates on regulatory changes. Together, these tools address the two core operational gaps: fragmented data and reactive intelligence that sit behind most of the delays and compliance issues regulatory teams face.
How is technology transforming regulatory teams?
Technology is enabling a shift from administrative regulatory operations to strategic regulatory management. By automating routine tasks (submission tracking, document routing, deadline management) and centralizing regulatory data, technology allows regulatory professionals to focus on higher-value work such as pathway strategy, agency engagement, risk assessment, and global market planning. AI is accelerating this shift, particularly in regulatory intelligence and gap analysis, but its value depends on data quality and process maturity. Organizations that invest in their regulatory data infrastructure now will be positioned to extract significantly more value from AI capabilities as they mature.
